. Author manuscript; available in PMC: 2017 Feb 1.

Published in final edited form as: Hepatology. 2015 Dec 21;63(2):428–436. doi: 10.1002/hep.28327

Table 4.

Scenarios in Which SOF/LDV is Cost-Effective Compared to 3D for Treating Veterans with Hepatitis C*

$50,000 per QALY	$100,000 per QALY
Cost of SOF/LDV <$2,250/week	Cost of SOF/LDV <$2,220/week
Cost of 3D >$3,195/week	Cost of 3D >$3,220/week
3D <86% effective for genotype 1a (F0–F3)	3D <91% effective for genotype 1a (F0–F3)
3D <80% effective for genotype 1b (F0–F3)	3D <89% effective for genotype 1b
	SOF/LDV 100% effective (F0–F3)

Note: Calculated using one-way sensitivity analyses comparing drug regimens for the "Treat Any" strategy. 3D: ombitasvir, ritonavir, paritaprevir, dasabuvir ± ribavirin, F0–F3: METAVIR Stages of Hepatic Fibrosis, SOF/LDV: sofosbuvir/ledipasvir